>>But the NKTR-214 data in melanoma/RCC/UC are ok (IMO) despite lower ORR in (early-look) Stage-2 cohorts.
But what do you make of the twitter comment by JQ in the thread below noting that in the first trial there were very few additional responses after the first scan?
A couple good data points on biomarkers via Priti Hegde, Director of Biomarkers at Roche.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.